Image de couverture de livre

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nicolas Richard, Mathurin Fumery
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
par: C. Ramos‐Belinchon, et autres
Publié: (2025)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
par: Nicolas Richard, et autres
Publié: (2026)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
par: Vincenzo Stranges, et autres
Publié: (2025)

Editorial: Upadacitinib in Perianal Crohn's Disease
par: Manjeet Kumar Goyal, et autres
Publié: (2026)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
par: Shlomi Cohen, et autres
Publié: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
par: Jeffrey D McCurdy, et autres
Publié: (2025)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
par: José Luis Rueda García, et autres
Publié: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
par: Virginia Solitano, et autres
Publié: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
par: Shinichiro Shinzaki, et autres
Publié: (2025)

Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply
par: Runqi Wang, et autres
Publié: (2026)

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series
par: Rahul S. Dalal, et autres
Publié: (2025)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
par: Péter Bacsur, et autres
Publié: (2024)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
par: Jeffrey D McCurdy, et autres
Publié: (2024)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
par: Stefano Siboni, et autres
Publié: (2026)

Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply
par: Lichao Qiao, et autres
Publié: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
par: María Chaparro, et autres
Publié: (2024)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
par: Nathan Grellier, et autres
Publié: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
par: Jeffrey D. McCurdy, et autres
Publié: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
par: José Luis Rueda García, et autres
Publié: (2026)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
par: Fai Fai Ho, et autres
Publié: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
par: Suprabhat Giri, et autres
Publié: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
par: Federica Tavaglione, et autres
Publié: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
par: Bharati Kochar, et autres
Publié: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
par: Eric Lawitz, et autres
Publié: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
par: Aakash Desai, et autres
Publié: (2025)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
par: Olga P. Nyssen, et autres
Publié: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
par: Chia‐Chih Kuo, et autres
Publié: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply
par: Rohit Mehtani, et autres
Publié: (2026)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
par: Aurelien Amiot, et autres
Publié: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
par: Jessica A. Fitzpatrick, et autres
Publié: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
par: Cristina Rubín de Célix, et autres
Publié: (2025)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
par: Ramin Ebrahimi, et autres
Publié: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
par: Samantha Baillie, et autres
Publié: (2025)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
par: Jessica D. Lee, et autres
Publié: (2025)

Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply
par: Stiliano Maimaris, et autres
Publié: (2025)

Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease
par: Mohammad Shehab, et autres
Publié: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
par: Simone Chin, et autres
Publié: (2025)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
par: Máté Szilcz, et autres
Publié: (2025)